Novartis
FDA places no penalties on Novartis after Zolgensma data manipulation investigation
April 2, 2020Business Services FDA, Novartis, regulators
The FDA has concluded its investigation into Novartis and its data manipulation of the gene therapy Zolgensma, and has decided …
Novartis reveals hard-hitting five-year data for its gene therapy Zolgensma in spinal muscular atrophy
March 25, 2020Research and Development Novartis, Zolgensma, gene therapy, pharma, spinal muscular atrophy
Novartis has revealed five-year data on its gene therapy Zolgensma, boasting that the one-time infusion demonstrated “rapid, significant and clinically …
Japan approves Novartis’ Zolgensma for spinal muscular atrophy in patients under two years old
March 19, 2020Sales and Marketing Japan, Novartis, Zolgensma, pharma, spinal muscular atrophy
Novartis has revealed that its gene therapy Zolgensma (onasemnogene abeparvovec) has secured approval from Japan’s Ministry of Health, Labour and …
Novartis’ subsidiary Sandoz agrees to pay $195 million to settle antitrust case
March 3, 2020Manufacturing and Production Novartis, US Courts, generic drugs, generics, price fixing, price-fixing
Novartis’ Sandoz will pay a $195 million criminal penalty to resolve charges that it conspired to price-fix, rig bids and …
Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration
February 18, 2020Manufacturing and Production, Sales and Marketing Beovu, Eylea, Novartis, Regeneron, macular degeneration, pharma
The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet …
Novartis establishes its new legal entity in Vietnam
January 22, 2020Research and Development Novartis, Novartis Vietnam, oncology, pharma
Novartis has inaugurated its new legal entity in Vietnam, Novartis Vietnam Co Ltd, and has become one of the first …
Novartis’ Mayzent granted license by the European Medicines Agency
January 21, 2020Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis
The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …
AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance
January 16, 2020Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis
AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …
Novartis’ ligelizumab tops Xolair in chronic spontaneous urticaria
January 9, 2020Research and Development Novartis, Xolair, ligelizumab
Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair …
Merck, Novartis and Allergan to raise US drug prices, following most of drug industry
January 6, 2020Manufacturing and Production Allgeran, Big Pharma, Merck, Novartis, drug, drug prices
Following most of the large pharmaceutical companies, Merck, Novartis and Allergan have chosen to raise their drug prices. Novartis is …
Novartis plans giveaways of world’s most expensive drug
December 19, 2019Business Services Novartis, Zolgensma, sma
Novartis plans to giveaway 50 doses of the world’s costliest single-dose treatment, Zolgensma, for babies under 2 years old, with …
Novartis abandons asthma drug after Phase 3 trial results
December 17, 2019Manufacturing and Production Novartis, Novartis. R&D, asthma, novartis r&d
Novartis have said it is not going forward with a new asthma drug, as the treatement failed its Phase 3 …
Novartis pulls fevipiprant development in asthma following trial failure
December 16, 2019Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure
Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …
Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration
December 13, 2019Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma
Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …
Novartis Kisqali shows superior survival rates to AstraZeneca’s Faslodex in advanced breast cancer
December 12, 2019Business Services Journal of Medicine, Novartis, menopause
Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in …
